Methylglyoxal bis (cyclopentylamidinohydrazone) (MGBCP): antitumor effect against human osteosarcoma cells and combined effect with methotrexate, adriamycin and 4-hydroperoxyifosfamide.
The antitumor effect of a polyamine biosynthetic pathway inhibitor methylglyoxal bis(cyclopentylamidinohydrazone) (MGBCP) on human osteosarcoma cell lines such as KHOS-240S, MG-63 and G-292 cells, and its effect in combination with anticancer drugs such as methotrexate (MTX), adriamycin (ADM) and 4-hydroperoxyfosfamide (HIFO) have been investigated. The growth of these cultured osteosarcoma cells was inhibited by MGBCP in a dose-dependent manner. Spermidine and spermine levels were dose-dependently depressed in these MGBCP-treated osteosarcoma cells. The antitumor effect of MGBCP was additively potentiated by combined treatment with MTX, ADM and HIFO, respectively.
Sonoda
J
J
Department of Orthopedic Surgery, Mie University, Japan.
Hibasami
H
H
Yamada
H
H
Fujinami
S
S
Nakashima
K
K
Ogihara
Y
Y
D000970:Antineoplastic Agents / Q000633:toxicity*; D001859:Bone Neoplasms; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000633:toxicity*; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007069:Ifosfamide / Q000031:analogs & derivatives* / Q000633:toxicity; D007700:Kinetics; D008727:Methotrexate / Q000633:toxicity*; D008935:Mitoguazone / Q000031:analogs & derivatives* / Q000633:toxicity; D012516:Osteosarcoma; D011073:Polyamines / Q000378:metabolism*; D011700:Putrescine / Q000378:metabolism; D013095:Spermidine / Q000378:metabolism; D013096:Spermine / Q000378:metabolism; D014407:Tumor Cells, Cultured
D000970:Antineoplastic Agents; D011073:Polyamines; C059234:methylglyoxal bis(cyclopentylamidinohydrazone); D013096:Spermine; C012353:hydroperoxyisophosphamide; D004317:Doxorubicin; D008935:Mitoguazone; D013095:Spermidine; D007069:Ifosfamide; D011700:Putrescine; D008727:Methotrexate